The search for an HIV prevention vaccine: latest news

The search for an HIV prevention vaccine resources

  • Vaccines

    HIV vaccine researchers are still looking for a vaccine that would offer a significant degree of protection against HIV infection....

    From: Preventing HIV

    Information level Level 4
  • Vaccines

    The promise of an effective HIV vaccine has always been just over the horizon, but more than 20 years after the identification of HIV, vaccines...

    From: HIV transmission & testing

    Information level Level 4

The search for an HIV prevention vaccine features

The search for an HIV prevention vaccine news from aidsmap

More news

The search for an HIV prevention vaccine news selected from other sources

  • HIV antibody VRC01LS safe prevention strategy for infants

    Subcutaneous doses of a broadly neutralizing monoclonal antibody, known as VRC01LS, given at birth and 12 weeks were well-tolerated by HIV-exposed infants, according to the results of an open-label safety and pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections. Researchers are studying VRC01LS in combination with ART to prevent HIV infection in neonates.

    12 March 2019 | Healio
  • CROI 2019: Thailand’s strides spanned HIV treatment, prevention and research

    he first HIV vaccine trials to yield signs of hope happened here. Thailand was also the first Asian country to eliminate mother-to-child transmission of HIV. Now, Thailand has achieved the first part of UNAIDS’ 90-90-90 targets: 98 percent of people infected with HIV know their status.

    06 March 2019 | Science Speaks
  • Mind the Gap: The Burden of HIV Among Racial and Ethnic Minority Groups and Their Participation in Preventive HIV Vaccine Clinical Trials

    An analysis conducted by the HIV Vaccine Trials Network (HVTN) observed an overall increase in the proportion of racial and ethnic minorities enrolled in Phase 1 and Phase 2A preventive HIV vaccine clinical trials in the United States between 2002 and 2016 compared to 1988 to 2002. The findings were published on December 5, 2018 in Public Health Reports.

    16 February 2019 | HIV Vaccine Trials Network
  • Emerging options: Doctors and advocates discuss treatment and prevention breakthroughs on the horizon

    Long-acting injectables, implantables, the dapivirine ring, vaccines, antibodies, rectal douches, and two-drug regimens.

    30 January 2019 | Positively Aware
  • HIV vaccine protects non-human primates from infection

    The new study shows that rhesus macaque monkeys can be prompted to produce neutralizing antibodies against one strain of HIV that resembles the resilient viral form that most commonly infects people, called a Tier 2 virus. The research also provides the first-ever estimate of vaccine-induced neutralizing antibody levels needed to protect against HIV.

    17 December 2018 | Scripps Institute
  • Roadmap reveals shortcut to recreate key HIV antibody for vaccines

    A team led by Duke Human Vaccine Institute researchers, publishing online Dec. 11 in the journal Immunity, reported that they have filled in a portion of the roadmap toward effective neutralization of HIV, identifying the steps that a critical HIV antibody takes to develop and maintain its ability to neutralize the virus.

    12 December 2018 | Eurekalert Inf Dis
  • Needles in a haystack: the quest for bnAbs

    HIV induces antibody responses in infected individuals, but only a few of these individuals manage to produce antibodies that are capable of viral neutralization—and even fewer produce antibodies that can neutralize different strains of HIV.

    01 December 2018 | Nature
  • Scientists unveil promising new HIV vaccine strategy

    A new candidate HIV vaccine from Scripps Research surmounts technical hurdles that stymied previous vaccine efforts, and stimulates a powerful anti-HIV antibody response in animal tests. The new vaccine strategy, described in a paper on November 23 in Science Advances, is based on the HIV envelope protein, Env. This complex, shape-shifting molecule has been notoriously difficult to produce in vaccines in a way that induces useful immunity to HIV. However, the Scripps Research scientists found a simple, elegant method for stabilizing Env proteins in the desired shape even for diverse strains of HIV. Mounted on virus-like particles to mimic a whole virus, the stabilized Env proteins elicited robust anti-HIV antibody responses in mice and rabbits. Candidate vaccines based on this strategy are now being tested in monkeys.

    27 November 2018 | Scripps Research Institute
  • Why Don’t We Have Vaccines Against Everything?

    Money is just the obvious obstacle. A few diseases, like H.I.V., so far have outwitted both the immune system and scientists.

    22 November 2018 | New York Times
  • Continued declines in HIV research funding put global prevention targets at great risk

    HIV prevention research funding continued to decline in 2017 for the fifth consecutive year, driven largely by a five-year low in US public sector funding, according to a report released today at the HIV Research for Prevention (HIVR4P 2018) conference in Madrid, Spain.

    26 October 2018 | HIV Prevention R&D Working Group
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.